Managing toxicities associated with immune checkpoint inhibitors

被引：5

作者：

Park, Jiyeon Joy ^{[1
]}

Arafath, Syed ^{[2
]}

Kumar, Samir T. ^{[3
]}

Sharma, Roopali ^{[4
]}

Dixit, Deepali ^{[5
]}

机构：

[1] Rutgers State Univ, Ernest Mario Sch Pharm, Rutherford, NJ 08854 USA

[2] Presbyterian Weill Cornell Med Ctr Jama, Oncol Clin Pharm Specialist New York, Jamaica, NY USA

[3] SUNY Downstate Med Ctr, Internal Med Resident, Brooklyn, NY USA

[4] Touro Coll, Sch Pharm, Infect Dis Specialist, New York, NY USA

[5] Robert Wood Johnson Univ Hosp Piscataway, Rutgers & Clin Pharm Specialist Crit Care, Ernest Mario Sch Pharm, Piscataway, NJ USA

来源：

JAAPA-JOURNAL OF THE AMERICAN ACADEMY OF PHYSICIAN ASSISTANTS | 2021年 / 34卷 / 06期

关键词：

immune checkpoint inhibitor; toxicity; cancer; immune-related adverse events; adverse reaction; overactivation; DERMATOLOGICAL ADVERSE EVENTS; CANCER-PATIENTS; IPILIMUMAB; MANAGEMENT; NIVOLUMAB; METAANALYSIS; PNEUMONITIS; ANTI-PD-1; BLOCKADE;

D O I：

10.1097/01.JAA.0000735760.65235.3c

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Recent development of immunotherapy has led to remarkable advancement in cancer therapy. Drugs that inhibit the cytotoxic T-lymphocyte-associated protein (CTLA-4) and programmed death-1 (PD-1) immune checkpoint pathways have shown improved patient survival. However, by altering the immune response to fight cancer, a new class of adverse reactions has emerged, known as immune-related adverse events. These adverse events are due to overactivation of the immune system in almost any organ of the body, can occur at any point in a patient's treatment course, and may become life-threatening. This article describes how to promptly recognize and manage these toxicities.

引用

下载

页码：32 / 39

页数：8

共 50 条

[21] Cutaneous toxicities associated with immune checkpoint inhibitors: An observational, pharmacovigilance study
Le, T.
Brown, I.
Taylor, M.
Deng, J.
Parthasarathy, V.
Bordeaux, Z. A.
Alphonse, M. P.
Alhariri, J.
Kang, S.
Semenov, Y.
Kwatra, S. G.
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2022, 142 (08) : S33 - S33
[22] Mechanisms and clinical manifestations of cardiovascular toxicities associated with immune checkpoint inhibitors
Baik, Alan H.
Tsai, Katy K.
Oh, David Y.
Aras, Mandar A.
CLINICAL SCIENCE, 2021, 135 (05) : 703 - 724
[23] Ocular Toxicities in Setting of Immune Checkpoint Inhibitors
Noble, Carl William
Thompson, Ian
Chaon, Benjamin
Gangaputra, Sapna
Kodati, Shilpa
Okeagu, Chinwe
Magone, Teresa
Sen, H. Nida Nida
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2018, 59 (09)
[24] Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study
Salem, Joe-Elie
Manouchehri, Ali
Moey, Melissa
Lebrun-Vignes, Benedicte
Bastarache, Lisa
Pariente, Antoine
Gobert, Aurelien
Spano, Jean-Philippe
Balko, Justin M.
Bonaca, Marc P.
Roden, Dan M.
Johnson, Douglas B.
Moslehi, Javid J.
LANCET ONCOLOGY, 2018, 19 (12): : 1579 - 1589
[25] Rheumatic Toxicities Associated with Immune Checkpoint Inhibitors: An Observational, Retrospective, Pharmacovigilance Study
Anquetil, Celine
Benveniste, Olivier
Moslehi, Javid
Johnson, Douglas
Lebrun-vignes, Benedicte
Lambotte, Olivier
Selam, Joe-Elie
Spano, Jean-Philippe
Allenbachl, Yves
ARTHRITIS & RHEUMATOLOGY, 2019, 71
[26] Toxicities associated with checkpoint inhibitors-an overview
Spiers, Laura
Coupe, Nicholas
Payne, Miranda
RHEUMATOLOGY, 2019, 58 : 7 - 16
[27] Molecular fingerprints of cardiovascular toxicities of immune checkpoint inhibitors
Gergely, Tamas G.
Drobni, Zsofia D.
Sayour, Nabil V.
Ferdinandy, Peter
Varga, Zoltan V.
BASIC RESEARCH IN CARDIOLOGY, 2024, : 187 - 205
[28] What about cardiovascular toxicities of immune checkpoint inhibitors?
Moreno Diaz, Raquel
Cazalla Garcia, Mario
Bautista Sanz, Maria Pilar
Gonzalez Davia, Rosa
Rosero Rodriguez, Adriana Carolina
EUROPEAN JOURNAL OF HOSPITAL PHARMACY, 2021, 28 (01) : 2 - 3
[29] Nebenwirkungsmanagement bei ImmuncheckpointinhibitionManaging toxicities of immune checkpoint inhibitors
Paul J Bröckelmann
Jessica C Hassel
Die Onkologie, 2024, 30 (7) : 565 - 573
[30] Cutaneous Toxicities of Immune Checkpoint Inhibitors: The Role of the Dermatologist
Tattersall, Ian William
Leventhal, Jonathan Scott
YALE JOURNAL OF BIOLOGY AND MEDICINE, 2020, 93 (01): : 123 - 132

← 1 2 3 4 5 →